Get quick answers to your questions about the article from our AI researcher chatbot
{'id': 'https://openalex.org/W2280113021', 'doi': None, 'title': 'Erlotinib is a well-tolerated alternate treatment for non-small cell lung cancer in cases of gefitinib-induced hepatotoxicity.', 'display_name': 'Erlotinib is a well-tolerated alternate treatment for non-small cell lung cancer in cases of gefitinib-induced hepatotoxicity.', 'publication_year': 2014, 'publication_date': '2014-09-01', 'ids': {'openalex': 'https://openalex.org/W2280113021', 'mag': '2280113021', 'pmid': 'https://pubmed.ncbi.nlm.nih.gov/25202117'}, 'language': 'en', 'primary_location': {'is_oa': False, 'landing_page_url': 'https://pubmed.ncbi.nlm.nih.gov/25202117', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S4306525036', 'display_name': 'PubMed', 'issn_l': None, 'issn': None, 'is_oa': False, 'is_in_doaj': False, 'is_core': False, 'host_organization': 'https://openalex.org/I1299303238', 'host_organization_name': 'National Institutes of Health', 'host_organization_lineage': ['https://openalex.org/I1299303238'], 'host_organization_lineage_names': ['National Institutes of Health'], 'type': 'repository'}, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}, 'type': 'article', 'type_crossref': 'journal-article', 'indexed_in': ['pubmed'], 'open_access': {'is_oa': False, 'oa_status': 'closed', 'oa_url': None, 'any_repository_has_fulltext': False}, 'authorships': [{'author_position': 'first', 'author': {'id': 'https://openalex.org/A5040004004', 'display_name': 'Kimio Yonesaka', 'orcid': 'https://orcid.org/0000-0002-0816-5315'}, 'institutions': [{'id': 'https://openalex.org/I4210132249', 'display_name': 'Izumi City General Hospital', 'ror': 'https://ror.org/03yj19r32', 'country_code': 'JP', 'type': 'healthcare', 'lineage': ['https://openalex.org/I4210132249']}], 'countries': ['JP'], 'is_corresponding': False, 'raw_author_name': 'Kimio Yonesaka', 'raw_affiliation_strings': ['Izumi Municipal Hospital, Department of Medical Oncology, Izumi, Osaka, Japan'], 'affiliations': [{'raw_affiliation_string': 'Izumi Municipal Hospital, Department of Medical Oncology, Izumi, Osaka, Japan', 'institution_ids': ['https://openalex.org/I4210132249']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5064620551', 'display_name': 'Tomohiro Suzumura', 'orcid': 'https://orcid.org/0000-0002-3785-5155'}, 'institutions': [{'id': 'https://openalex.org/I4210132249', 'display_name': 'Izumi City General Hospital', 'ror': 'https://ror.org/03yj19r32', 'country_code': 'JP', 'type': 'healthcare', 'lineage': ['https://openalex.org/I4210132249']}], 'countries': ['JP'], 'is_corresponding': False, 'raw_author_name': 'Tomohiro Suzumura', 'raw_affiliation_strings': ['Izumi Municipal Hospital, Department of Medical Oncology, Izumi, Osaka, Japan'], 'affiliations': [{'raw_affiliation_string': 'Izumi Municipal Hospital, Department of Medical Oncology, Izumi, Osaka, Japan', 'institution_ids': ['https://openalex.org/I4210132249']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5071709095', 'display_name': 'Hiroshi Tsukuda', 'orcid': None}, 'institutions': [{'id': 'https://openalex.org/I4210132249', 'display_name': 'Izumi City General Hospital', 'ror': 'https://ror.org/03yj19r32', 'country_code': 'JP', 'type': 'healthcare', 'lineage': ['https://openalex.org/I4210132249']}], 'countries': ['JP'], 'is_corresponding': False, 'raw_author_name': 'Hiroshi Tsukuda', 'raw_affiliation_strings': ['Izumi Municipal Hospital, Department of Medical Oncology, Izumi, Osaka, Japan'], 'affiliations': [{'raw_affiliation_string': 'Izumi Municipal Hospital, Department of Medical Oncology, Izumi, Osaka, Japan', 'institution_ids': ['https://openalex.org/I4210132249']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5112499724', 'display_name': 'Yoshikazu Hasegawa', 'orcid': None}, 'institutions': [{'id': 'https://openalex.org/I4210132249', 'display_name': 'Izumi City General Hospital', 'ror': 'https://ror.org/03yj19r32', 'country_code': 'JP', 'type': 'healthcare', 'lineage': ['https://openalex.org/I4210132249']}], 'countries': ['JP'], 'is_corresponding': False, 'raw_author_name': 'Yoshikazu Hasegawa', 'raw_affiliation_strings': ['Izumi Municipal Hospital, Department of Medical Oncology, Izumi, Osaka, Japan'], 'affiliations': [{'raw_affiliation_string': 'Izumi Municipal Hospital, Department of Medical Oncology, Izumi, Osaka, Japan', 'institution_ids': ['https://openalex.org/I4210132249']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5065856332', 'display_name': 'Tomohiro Ozaki', 'orcid': 'https://orcid.org/0000-0002-8178-4171'}, 'institutions': [{'id': 'https://openalex.org/I4210132249', 'display_name': 'Izumi City General Hospital', 'ror': 'https://ror.org/03yj19r32', 'country_code': 'JP', 'type': 'healthcare', 'lineage': ['https://openalex.org/I4210132249']}], 'countries': ['JP'], 'is_corresponding': False, 'raw_author_name': 'Tomohiro Ozaki', 'raw_affiliation_strings': ['Izumi Municipal Hospital, Department of Medical Oncology, Izumi, Osaka, Japan'], 'affiliations': [{'raw_affiliation_string': 'Izumi Municipal Hospital, Department of Medical Oncology, Izumi, Osaka, Japan', 'institution_ids': ['https://openalex.org/I4210132249']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5005997657', 'display_name': 'T Sugiura', 'orcid': None}, 'institutions': [{'id': 'https://openalex.org/I4210132249', 'display_name': 'Izumi City General Hospital', 'ror': 'https://ror.org/03yj19r32', 'country_code': 'JP', 'type': 'healthcare', 'lineage': ['https://openalex.org/I4210132249']}], 'countries': ['JP'], 'is_corresponding': False, 'raw_author_name': 'Takamune Sugiura', 'raw_affiliation_strings': ['Izumi Municipal Hospital, Department of Medical Oncology, Izumi, Osaka, Japan'], 'affiliations': [{'raw_affiliation_string': 'Izumi Municipal Hospital, Department of Medical Oncology, Izumi, Osaka, Japan', 'institution_ids': ['https://openalex.org/I4210132249']}]}, {'author_position': 'last', 'author': {'id': 'https://openalex.org/A5108393803', 'display_name': 'Masahiro Fukuoka', 'orcid': None}, 'institutions': [{'id': 'https://openalex.org/I4210132249', 'display_name': 'Izumi City General Hospital', 'ror': 'https://ror.org/03yj19r32', 'country_code': 'JP', 'type': 'healthcare', 'lineage': ['https://openalex.org/I4210132249']}], 'countries': ['JP'], 'is_corresponding': False, 'raw_author_name': 'Masahiro Fukuoka', 'raw_affiliation_strings': ['Izumi Municipal Hospital, Department of Medical Oncology, Izumi, Osaka, Japan'], 'affiliations': [{'raw_affiliation_string': 'Izumi Municipal Hospital, Department of Medical Oncology, Izumi, Osaka, Japan', 'institution_ids': ['https://openalex.org/I4210132249']}]}], 'institution_assertions': [], 'countries_distinct_count': 1, 'institutions_distinct_count': 1, 'corresponding_author_ids': [], 'corresponding_institution_ids': [], 'apc_list': None, 'apc_paid': None, 'fwci': 1.777, 'has_fulltext': False, 'cited_by_count': 11, 'citation_normalized_percentile': {'value': 0.8217, 'is_in_top_1_percent': False, 'is_in_top_10_percent': False}, 'cited_by_percentile_year': {'min': 86, 'max': 87}, 'biblio': {'volume': '34', 'issue': '9', 'first_page': '5211', 'last_page': '5'}, 'is_retracted': False, 'is_paratext': False, 'primary_topic': {'id': 'https://openalex.org/T10417', 'display_name': 'Lung Cancer Treatments and Mutations', 'score': 1.0, 'subfield': {'id': 'https://openalex.org/subfields/2740', 'display_name': 'Pulmonary and Respiratory Medicine'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, 'topics': [{'id': 'https://openalex.org/T10417', 'display_name': 'Lung Cancer Treatments and Mutations', 'score': 1.0, 'subfield': {'id': 'https://openalex.org/subfields/2740', 'display_name': 'Pulmonary and Respiratory Medicine'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, {'id': 'https://openalex.org/T10231', 'display_name': 'Pancreatic and Hepatic Oncology Research', 'score': 0.9979, 'subfield': {'id': 'https://openalex.org/subfields/2730', 'display_name': 'Oncology'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, {'id': 'https://openalex.org/T11067', 'display_name': 'Colorectal Cancer Treatments and Studies', 'score': 0.9977, 'subfield': {'id': 'https://openalex.org/subfields/2730', 'display_name': 'Oncology'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}], 'keywords': [{'id': 'https://openalex.org/keywords/tolerability', 'display_name': 'Tolerability', 'score': 0.6493541}, {'id': 'https://openalex.org/keywords/erlotinib-hydrochloride', 'display_name': 'Erlotinib Hydrochloride', 'score': 0.5271929}], 'concepts': [{'id': 'https://openalex.org/C2780580887', 'wikidata': 'https://www.wikidata.org/wiki/Q417824', 'display_name': 'Gefitinib', 'level': 4, 'score': 0.9852501}, {'id': 'https://openalex.org/C2778087573', 'wikidata': 'https://www.wikidata.org/wiki/Q418369', 'display_name': 'Erlotinib', 'level': 4, 'score': 0.9819834}, {'id': 'https://openalex.org/C71924100', 'wikidata': 'https://www.wikidata.org/wiki/Q11190', 'display_name': 'Medicine', 'level': 0, 'score': 0.82700145}, {'id': 'https://openalex.org/C2776256026', 'wikidata': 'https://www.wikidata.org/wiki/Q47912', 'display_name': 'Lung cancer', 'level': 2, 'score': 0.68410987}, {'id': 'https://openalex.org/C2778375690', 'wikidata': 'https://www.wikidata.org/wiki/Q7814214', 'display_name': 'Tolerability', 'level': 3, 'score': 0.6493541}, {'id': 'https://openalex.org/C2779438470', 'wikidata': 'https://www.wikidata.org/wiki/Q424401', 'display_name': 'Epidermal growth factor receptor', 'level': 3, 'score': 0.5980458}, {'id': 'https://openalex.org/C2909325608', 'wikidata': 'https://www.wikidata.org/wiki/Q418369', 'display_name': 'Erlotinib Hydrochloride', 'level': 5, 'score': 0.5271929}, {'id': 'https://openalex.org/C143998085', 'wikidata': 'https://www.wikidata.org/wiki/Q162555', 'display_name': 'Oncology', 'level': 1, 'score': 0.49299952}, {'id': 'https://openalex.org/C126322002', 'wikidata': 'https://www.wikidata.org/wiki/Q11180', 'display_name': 'Internal medicine', 'level': 1, 'score': 0.48292467}, {'id': 'https://openalex.org/C98274493', 'wikidata': 'https://www.wikidata.org/wiki/Q128406', 'display_name': 'Pharmacology', 'level': 1, 'score': 0.4100303}, {'id': 'https://openalex.org/C121608353', 'wikidata': 'https://www.wikidata.org/wiki/Q12078', 'display_name': 'Cancer', 'level': 2, 'score': 0.29918858}, {'id': 'https://openalex.org/C197934379', 'wikidata': 'https://www.wikidata.org/wiki/Q2047938', 'display_name': 'Adverse effect', 'level': 2, 'score': 0.21220413}], 'mesh': [{'descriptor_ui': 'D000970', 'descriptor_name': 'Antineoplastic Agents', 'qualifier_ui': 'Q000627', 'qualifier_name': 'therapeutic use', 'is_major_topic': True}, {'descriptor_ui': 'D002289', 'descriptor_name': 'Carcinoma, Non-Small-Cell Lung', 'qualifier_ui': 'Q000188', 'qualifier_name': 'drug therapy', 'is_major_topic': True}, {'descriptor_ui': 'D008175', 'descriptor_name': 'Lung Neoplasms', 'qualifier_ui': 'Q000188', 'qualifier_name': 'drug therapy', 'is_major_topic': True}, {'descriptor_ui': 'D047428', 'descriptor_name': 'Protein Kinase Inhibitors', 'qualifier_ui': 'Q000627', 'qualifier_name': 'therapeutic use', 'is_major_topic': True}, {'descriptor_ui': 'D011799', 'descriptor_name': 'Quinazolines', 'qualifier_ui': 'Q000627', 'qualifier_name': 'therapeutic use', 'is_major_topic': True}, {'descriptor_ui': 'D000328', 'descriptor_name': 'Adult', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D000368', 'descriptor_name': 'Aged', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D000369', 'descriptor_name': 'Aged, 80 and over', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D000970', 'descriptor_name': 'Antineoplastic Agents', 'qualifier_ui': 'Q000009', 'qualifier_name': 'adverse effects', 'is_major_topic': False}, {'descriptor_ui': 'D000970', 'descriptor_name': 'Antineoplastic Agents', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D000970', 'descriptor_name': 'Antineoplastic Agents', 'qualifier_ui': 'Q000008', 'qualifier_name': 'administration & dosage', 'is_major_topic': False}, {'descriptor_ui': 'D002289', 'descriptor_name': 'Carcinoma, Non-Small-Cell Lung', 'qualifier_ui': 'Q000150', 'qualifier_name': 'complications', 'is_major_topic': False}, {'descriptor_ui': 'D002289', 'descriptor_name': 'Carcinoma, Non-Small-Cell Lung', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D002289', 'descriptor_name': 'Carcinoma, Non-Small-Cell Lung', 'qualifier_ui': 'Q000473', 'qualifier_name': 'pathology', 'is_major_topic': False}, {'descriptor_ui': 'D056486', 'descriptor_name': 'Chemical and Drug Induced Liver Injury', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D057915', 'descriptor_name': 'Drug Substitution', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D000069347', 'descriptor_name': 'Erlotinib Hydrochloride', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D005260', 'descriptor_name': 'Female', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D000077156', 'descriptor_name': 'Gefitinib', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D006801', 'descriptor_name': 'Humans', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D008175', 'descriptor_name': 'Lung Neoplasms', 'qualifier_ui': 'Q000150', 'qualifier_name': 'complications', 'is_major_topic': False}, {'descriptor_ui': 'D008175', 'descriptor_name': 'Lung Neoplasms', 'qualifier_ui': 'Q000473', 'qualifier_name': 'pathology', 'is_major_topic': False}, {'descriptor_ui': 'D008175', 'descriptor_name': 'Lung Neoplasms', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D008297', 'descriptor_name': 'Male', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D008875', 'descriptor_name': 'Middle Aged', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D009367', 'descriptor_name': 'Neoplasm Staging', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D047428', 'descriptor_name': 'Protein Kinase Inhibitors', 'qualifier_ui': 'Q000008', 'qualifier_name': 'administration & dosage', 'is_major_topic': False}, {'descriptor_ui': 'D047428', 'descriptor_name': 'Protein Kinase Inhibitors', 'qualifier_ui': 'Q000009', 'qualifier_name': 'adverse effects', 'is_major_topic': False}, {'descriptor_ui': 'D047428', 'descriptor_name': 'Protein Kinase Inhibitors', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D011799', 'descriptor_name': 'Quinazolines', 'qualifier_ui': 'Q000009', 'qualifier_name': 'adverse effects', 'is_major_topic': False}, {'descriptor_ui': 'D011799', 'descriptor_name': 'Quinazolines', 'qualifier_ui': 'Q000008', 'qualifier_name': 'administration & dosage', 'is_major_topic': False}, {'descriptor_ui': 'D011799', 'descriptor_name': 'Quinazolines', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D016896', 'descriptor_name': 'Treatment Outcome', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}], 'locations_count': 1, 'locations': [{'is_oa': False, 'landing_page_url': 'https://pubmed.ncbi.nlm.nih.gov/25202117', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S4306525036', 'display_name': 'PubMed', 'issn_l': None, 'issn': None, 'is_oa': False, 'is_in_doaj': False, 'is_core': False, 'host_organization': 'https://openalex.org/I1299303238', 'host_organization_name': 'National Institutes of Health', 'host_organization_lineage': ['https://openalex.org/I1299303238'], 'host_organization_lineage_names': ['National Institutes of Health'], 'type': 'repository'}, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}], 'best_oa_location': None, 'sustainable_development_goals': [{'score': 0.86, 'display_name': 'Good health and well-being', 'id': 'https://metadata.un.org/sdg/3'}], 'grants': [], 'datasets': [], 'versions': [], 'referenced_works_count': 17, 'referenced_works': ['https://openalex.org/W1981989535', 'https://openalex.org/W2016852257', 'https://openalex.org/W2026191808', 'https://openalex.org/W2043696829', 'https://openalex.org/W2111662961', 'https://openalex.org/W2119366998', 'https://openalex.org/W2123029393', 'https://openalex.org/W2129360604', 'https://openalex.org/W2132157071', 'https://openalex.org/W2151126163', 'https://openalex.org/W2152171507', 'https://openalex.org/W2160982674', 'https://openalex.org/W2161821474', 'https://openalex.org/W2164738374', 'https://openalex.org/W2166084034', 'https://openalex.org/W2166498198', 'https://openalex.org/W2167368130'], 'related_works': ['https://openalex.org/W3143948814', 'https://openalex.org/W2801303484', 'https://openalex.org/W2354091825', 'https://openalex.org/W2319187913', 'https://openalex.org/W2217699725', 'https://openalex.org/W2186047679', 'https://openalex.org/W2088932689', 'https://openalex.org/W2080533419', 'https://openalex.org/W2005973176', 'https://openalex.org/W1524782789'], 'abstract_inverted_index': {'To': [0], 'evaluate': [1], 'the': [2, 72], 'tolerability': [3], 'and': [4, 65, 124], 'efficacy': [5, 66], 'of': [6, 44, 67, 71, 111], 'erlotinib': [7, 57, 68, 79, 92], 'treatment': [8, 53, 121], 'in': [9, 60, 126], 'advanced': [10], 'non-small': [11], 'cell': [12], 'lung': [13], 'cancer': [14], '(NSCLC)': [15], 'patients': [16, 27, 74, 85, 128], 'who': [17], 'had': [18], 'previously': [19], 'experienced': [20, 46], 'severe': [21, 47, 76, 82, 119, 134], 'hepatotoxicity': [22, 77, 135], 'after': [23, 101], 'gefitinib': [24, 39, 89, 98, 117, 138], 'treatment.Twenty-five': [25], 'NSCLC': [26, 127], 'with': [28, 38, 78, 88, 97, 129, 136], 'epidermal': [29], 'growth': [30], 'factor': [31], 'receptor': [32], '(EGFR)': [33], 'mutation': [34], 'were': [35, 69], 'initially': [36], 'treated': [37], '(250': [40], 'mg/day).': [41], 'However,': [42], '7': [43, 62, 73], 'these': [45], 'hepatotoxicity.': [48, 83], 'After': [49], 'recovery': [50], 'from': [51], 'hepatotoxicity,': [52], 'was': [54, 99, 114, 122], 'switched': [55], 'to': [56, 103], '(150': [58], 'mg/day)': [59], 'all': [61], 'patients.': [63], 'Toxicity': [64], 'analyzed.None': [70], 'reported': [75], 'despite': [80, 132], 'gefitinib-induced': [81], 'All': [84], 'achieved': [86, 96, 115], 'response': [87, 95], 'or': [90], 'following': [91], 'treatment.': [93, 139], 'The': [94], 'maintained': [100], 'switching': [102], 'erlotinib.': [104], 'Therefore,': [105], 'an': [106], 'excellent': [107], 'median': [108], 'progression-free': [109], 'survival': [110], '372': [112], 'days': [113], 'although': [116], 'induced': [118], 'hepatotoxicity.Erlotinib': [120], 'efficient': [123], 'well-tolerated': [125], 'EGFR': [130], 'mutation,': [131], 'their': [133], 'prior': [137]}, 'cited_by_api_url': 'https://api.openalex.org/works?filter=cites:W2280113021', 'counts_by_year': [{'year': 2023, 'cited_by_count': 1}, {'year': 2020, 'cited_by_count': 2}, {'year': 2019, 'cited_by_count': 1}, {'year': 2017, 'cited_by_count': 2}, {'year': 2016, 'cited_by_count': 3}, {'year': 2015, 'cited_by_count': 1}, {'year': 2014, 'cited_by_count': 1}], 'updated_date': '2024-12-09T10:38:04.451668', 'created_date': '2016-06-24'}